About aktiia

aktiia is a Swiss startup founded in May 2018 by Mattia Bertschi (CEO) and Josep Sola (CTO). The team currently counts 9 employees with offices in Neode/Microcity Neuchatel (Switzerland) and Zürich (Switzerland). aktiia’s patented core technology for blood pressure monitoring is based on more than 15 years of pioneering work and over 30 peer-reviewed publications at the Swiss research and technology organization CSEM. aktiia’s technology combines common optical sensors and clinically validated software algorithms to measure an individual’s blood pressure at the wrist. The technology has been validated through trials in acute and low-acute settings with worldwide acknowledgement of its accuracy. aktiia will embed its technology in non-medical third-party wearables for preventive purpose and in its own medical-grade wearable for diagnosis and management of hypertension.

Press release

September 25, 2018 – aktiia Closes 4 M Seed Round

aktiia Closes 4M Seed Round to Reinvent Blood Pressure Monitoring

Neuchâtel, September 25th, 2018 – aktiia, a technology company founded by leading experts from the Swiss research institute CSEM, raised CHF 4 million in seed round to commercialize its disruptive algorithms for blood pressure monitoring.

“There’s an urgent need to address the problem of hypertension, as it affects every third adult, and is the largest epidemic known to mankind. We will empower people with cutting edge technology in this fight.”, said Mattia Bertschi, co-founder and CEO.

aktiia’s technology combines common optical sensors, widely-known for tracking heart-rate in today’s wearables, and clinically validated software algorithms to measure an individual’s blood pressure at the wrist. The algorithms will be embedded in non-medical third-party wearables for preventive purpose to track blood pressure trends, as well as in aktiia’s medical grade wearable to monitor precise blood pressure values that can be used for the diagnosis and management of hypertension.

The development of aktiia’s patented technology is directed by the co-founder and CTO, Josep Sola, a pioneering expert in the field. “This technology is a quantum leap in the fight against hypertension and will revolutionize the way we look at blood pressure.” stated Michael Sidler, Co-Founder and Partner of Redalpine.

Led by the Silicon Valley based TransLink Capital, and Swiss based Redalpine, the funding will fuel aktiia in achieving its goal of getting hypertension monitors to those who need it most. The seed round also includes strategically recruited international angel investors: Christian Wenger (Switzerland), Mladen Barbaric of Pearl Studios (Canada), and Sparks Street Capital (USA), underpinning the company with a global network and commercialization experience.

“TransLink has always been on the forefront of wearable technologies, and we are constantly on the lookout for pioneers. We are very excited to be a part of what will be a healthcare game changer.” said Eric Hsia, Managing Director of TransLink Capital.

aktiia is currently developing both strategic third-party manufacturer partnerships, as well as its full product offering.

About aktiia

aktiia is a Swiss startup founded in May 2018 by Mattia Bertschi (CEO) and Josep Sola (CTO). The team currently counts 10 employees and is located in Neuchatel (Switzerland) and Zürich (Switzerland). aktiia’s patented core technology for blood pressure monitoring is based on more than 15 years of pioneering work and over 30 peer-reviewed publications at the Swiss research and technology organization CSEM. aktiia’s technology combines common optical sensors and clinically validated software algorithms to measure an individual’s blood pressure at the wrist.The technology has been validated through trials in acute and low-acute settings with worldwide acknowledgement of its accuracy.

About TransLink Capital

Based in Palo Alto, California, with offices in Beijing, Taipei, Tokyo and Seoul, TransLink Capital invests in technology startups that benefit from the firm’s long-standing strategic relationships with the leading Asian information technology, internet, telecommunications, and financial services corporations across Greater China, Japan, and South Korea.

About Redalpine

Redalpine is a European early-stage investor, focusing on highly scalable ICT and Health-Tech ventures. Established in 2007 by a group of successful serial entrepreneurs, Redalpine empowers talented entrepreneurs to turn ambitious visions into reality by providing funding, guidance and an expansive business network.

Mai 22, 2018 : Creation of aktiia SA

Creation of aktiia SA – The Optical Revolution for Blood Pressure Monitoring

CSEM announces the creation of a new startup, aktiia SA, which has been launched to commercialize its proprietary cuffless optical Blood Pressure Monitoring technology (oBPMTM). By offering continuous and accurate blood pressure measurement at the wrist, the creation of aktiia represents a major step forward in the precise long-term monitoring, diagnosis and treatment of hypertension as well as the fight against cardiovascular diseases.

The Biggest Epidemic Ever Known to Mankind

According to the World Health Organization, one in three adults suffer from hypertension – that is 1.5 billion adults worldwide. Hypertension can lead to severe complications, such as stroke and heart failure. Each year, this illness results in 7.5 million premature deaths worldwide. The paradox of hypertension is that most people suffering from this condition are unaware of it. As such, hypertension is known as the «silent killer». Furthermore, the current «gold standard» for blood pressure measurement is performed with a cuff placed around the arm. This 110 years old technology is cumbersome and leads to low compliance for patients prescribed to self-monitor. As a consequence, healthcare professionals lack access to complete and highquality data for their diagnosis and the treatment of this disease.

Facing Hypertension with a Strong Team and a Proven Track Record

Awarded the Neode Prize 2017, Josep Solà and Mattia Bertschi, together with their team at CSEM, developed the revolutionary cuffless optical Blood Pressure Monitoring technology (oBPM™). oBPM™ combines common optical sensors and clinically validated software algorithms to measure an individual’s blood pressure at the wrist. aktiia builds on a strong patent portfolio, over 15 years of CSEM experience in the field of non-occlusive blood pressure monitoring, more than 30 peer-reviewed publications, clinical trials in acute and low-acute settings, and worldwide acknowledgement of its accuracy. In the past months, the co-founders of the company, Mattia Bertschi (CEO) and Josep Sola (CTO), together with Tobias Pforr (Chief Marketing Officer), have built up a strong management team supported by leading US and Swiss venture capital investors. In the coming months, aktiia will be building a global team with offices in Switzerland and the US and expand its global strategic partnership network in Europe and the US.

Launch of the First Accurate Blood Pressure Monitor Solely Based on Optical Measurements

In the coming months, aktiia will release its technology in form of a CE-certified and FDA-approved medical wrist wearable that will seamlessly integrate into people’s lives. Having robust and detailed yet comfortable monitoring of one’s blood pressure will allow patients and healthcare professionals alike to better understand the underlying causes of high blood pressure in order to develop new approaches to deal with this limiting and life-threatening condition.

By deploying an accurate and comfortable technology for the diagnosis and management of hypertension, aktiia’s mission is to contribute to prevention, to save lives and to help reduce healthcare costs worldwide. Be part of this revolution and get in touch